This article has been corrected to fix erroneous information regarding Qiagen. The firm's Q4 revenues increased 5 percent, not decreased 5 percent, as the previous version of the article stated. Also, Qiagen didn't sign a recent companion diagnostic alliance with Amgen.

NEW YORK (GenomeWeb News) – Illumina, Pacific Biosciences, and Myriad Genetics led a group of companies which saw their stocks increase more than 20 percent in January from December as the GenomeWeb Daily News Index rose nearly 7 percent month over month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.